| Literature DB >> 26515736 |
Abstract
There is an increasing use of established and newer medications that have antiangiogenic properties. Inhibition of angiogenesis likely has either a primary or secondary role in the development of osteonecrosis of the jaw (ONJ). These medications are being used in the treatment of various cancers and in the treatment of several non-oncologic conditions. Antiangiogenic medications when used in combination with antiresorptive medications, such as nitrogen-containing bisphosphonates or denosumab, seem to increase the likelihood of osteonecrosis of the jaw. This review highlights the role of inhibitors of angiogenesis and their role in the development of osteonecrosis of the jaws.Entities:
Keywords: Antiangiogenic therapy; Denosumab; Mammalian target of rapamycin inhibitors; Nitrogen-containing bisphosphonates; Receptor activator of nuclear factor-κB ligand inhibitors; Tyrosine kinase inhibitors; Vascular endothelial growth factor inhibitors
Mesh：
Substances：
Year: 2015 PMID： 26515736 DOI： 10.1016/j.coms.2015.06.004
Source DB: PubMed Journal: Oral Maxillofac Surg Clin North Am ISSN： 1042-3699 Impact factor: 2.802